Pharmacokinetic-pharmacodynamic assessment of faropenem in a lethal murine Bacillus anthracis inhalation postexposure prophylaxis model

Antimicrobial Agents and Chemotherapy

Volumn 54, Issue 5, 2010, Pages 1678-1683

  Gill, Stanley C ^a   Rubino, Christopher M ^b   Bassett, Jennifer ^c   Miller, Lynda ^c   Ambrose, Paul G ^b   Bhavnani, Sujata M ^b   Beaudry, Amber ^a   Li, Jinfang ^a   Stone, Kimberly Clawson ^a   Critchley, Ian ^a   Janjic, Nebojsa ^a   Heine, Henry S ^c  

^a Replidyne Inc   (United States)

^b ORDWAY RESEARCH INSTITUTE   (United States)

^c UNITED STATES ARMY MEDICAL RESEARCH INSTITUTE OF INFECTIOUS DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CIPROFLOXACIN; FROPENEM;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTHRAX; ANTIBIOTIC PROPHYLAXIS; ARTICLE; BACILLUS ANTHRACIS; BODY WEIGHT; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; LETHAL DOSE; MINIMUM INHIBITORY CONCENTRATION; MOUSE; NONHUMAN; PHARMACODYNAMICS; PRIORITY JOURNAL; SINGLE DRUG DOSE; STEADY STATE; SURVIVAL;

ANIMALS; ANTHRAX; ANTI-BACTERIAL AGENTS; BACILLUS ANTHRACIS; BETA-LACTAMASES; BETA-LACTAMS; BLOOD PROTEINS; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; INHALATION EXPOSURE; MICE; MICE, INBRED BALB C; MODELS, BIOLOGICAL;

EID: 77951235474     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00737-08     Document Type: Article

References (17)

1. Ambrose, P. G., A. Forrest, W. A. Craig, C. M. Rubino, S. M. Bhavnani, G. L. Drusano, and H. S. Heine. 2007. Pharmacokinetics-pharmacodynamics of gatifloxacin in a lethal murine Bacillus anthracis inhalation infection model. Antimicrob. Agents Chemother. 51:4351-4355.
2. Beharry, Z., H. Chen, V. R. Gadhachanda, J. D. Buynak, and T. Palzkill. 2004. Evaluation of penicillin-based inhibitors of the class A and B beta-lactamases from Bacillus anthracis. Biochem. Biophys. Res. Commun. 313: 541-545.
3. Black, J. A., E. Smith Moland, T. J. Lockhart, P. D. Lister, and K. S. Thomson. 2001. Faropenem: activity against ESBL, AmpC, and other β-lactamase-producing Enterobacteriaceae, abstr. E-791. Abstr. 41st Intersci. Conf. Antimicrob. Agents Chemother. American Society for Microbiology, Washington, DC.
4. Chen, Y., J. Succi, F. C. Tenover, and T. M. Koehler. 2003. Beta-lactamase genes of the penicillin-susceptible Bacillus anthracis Sterne strain. J. Bacteriol. 185:823-830.
5. Chen, Y., F. C. Tenover, and T. M. Koehler. 2004. Beta-lactamase gene expression in a penicillin-resistant Bacillus anthracis strain. Antimicrob. Agents Chemother. 48:4873-4877.
6. Clinical and Laboratory Standards Institute. 2007. Performance standards for antimicrobial susceptibility testing, 17th informational supplement. M100-S17. Clinical and Laboratory Standards Institute, Wayne, PA.
7. Craig, W. A. 2003. Basic pharmacodynamics of antibacterials with clinical applications to the use of beta-lactams, glycopeptides, and linezolid. Infect. Dis. Clin. North Am. 17:479-501.
8. Craig, W. A., and D. R. Andes. 2001. In vivo pharmacodynamic activity of faropenem against Streptococcus pneumoniae, abstr. A-2094. Abstr. 41st Intersci. Conf. Antimicrob. Agents Chemother. American Society for Microbiology, Washington, DC.
9. Dalhoff, A., N. Janjic, and R. Echols. 2006. Redefining penems. Biochem. Pharmacol. 71:1085-1095.
10. Gill, S., and R. Tosiello. 2006. Abstr. 46th Intersci. Conf. Antimicrob. Agents Chemother., abstr. A-1492.
11. Heine, H. S., J. Bassett, L. Miller, J. M. Hartings, B. E. Ivins, M. L. Pitt, D. Fritz, S. L. Norris, and W. R. Byrne. 2007. Determination of antibiotic efficacy against Bacillus anthracis in a mouse aerosol challenge model. Antimicrob. Agents Chemother. 51:1373-1379.
12. Jarvis, T. C., K. Clawson Stone, I. A. Critchley, S. C. Gill, and N. Janjic. 2005. Abstr. 45th Intersci. Conf. Antimicrob. Agents Chemother., abstr. A-6.
13. Keim, P., L. B. Price, A. M. Klevytska, K. L. Smith, J. M. Schupp, R. Okinaka, P. J. Jackson, and M. E. Hugh-Jones. 2000. Multiple-locus variable-number tandem repeat analysis reveals genetic relationships within Bacillus anthracis. J. Bacteriol. 182:2928-2936.
14. Mohammed, M. J., C. K. Marston, T. Popovic, R. S. Weyant, and F. C. Tenover. 2002. Antimicrobial susceptibility testing of Bacillus anthracis: comparison of results obtained by using the National Committee for Clinical Laboratory Standards broth microdilution reference and Etest agar gradient diffusion methods. J. Clin. Microbiol. 40:1902-1907.
15. National Research Council. 1996. Guide for the care and use of laboratory animals. National Academy Press, Washington, DC.
16. Siegert, R., O. Berg, P. Gehanno, A. Leiberman, J. L. Martinkenas, P. Nikolaidis, P. Arvis, M. Alefelder, and P. Reimnitz. 2003. Comparison of the efficacy and safety of faropenem daloxate and cefuroxime axetil for the treatment of acute bacterial maxillary sinusitis in adults. Eur. Arch. Otorhinolaryngol. 260:186-194.
17. Upchurch, J., M. Rosemore, R. Tosiello, S. Kowalsky, and R. Echols. 2006. Randomized double-blind study comparing 7- and 10-day regimens of faropenem medoxomil with a 10-day cefuroxime axetil regimen for treatment of acute bacterial sinusitis. Otolaryngol. Head Neck Surg. 135:511-517.